company background image
1530 logo

3SBio SHSC:1530 Stock Report

Last Price

HK$5.97

Market Cap

HK$14.3b

7D

10.6%

1Y

-26.2%

Updated

25 Mar, 2024

Data

Company Financials +

1530 Stock Overview

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

3SBio Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 3SBio
Historical stock prices
Current Share PriceHK$5.97
52 Week HighHK$8.39
52 Week LowHK$4.91
Beta0.75
1 Month Change10.97%
3 Month Change-10.23%
1 Year Change-26.21%
3 Year Change-13.48%
5 Year Change-61.08%
Change since IPO-39.33%

Recent News & Updates

Recent updates

Shareholder Returns

1530HK BiotechsHK Market
7D10.6%-5.5%-1.2%
1Y-26.2%-43.0%-12.2%

Return vs Industry: 1530 exceeded the Hong Kong Biotechs industry which returned -42.8% over the past year.

Return vs Market: 1530 underperformed the Hong Kong Market which returned -13.4% over the past year.

Price Volatility

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement7.8%
Biotechs Industry Average Movement9.9%
Market Average Movement7.3%
10% most volatile stocks in HK Market14.7%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 1530's share price has been volatile over the past 3 months.

Volatility Over Time: 1530's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19935,311Jing Louhttps://www.3sbio.com

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Interferon, a human interferon a2a for injection; and Inleusin, for the treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer and tuberculosis. It also offers YISAIPU, the receptor-antibody fusion tumor necrosis factor inhibitor; Mendi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium; and Xenopax, a recombinant humanized anti-cd25 monoclonal antibody injection for prevention of acute rejection after renal transplantation.

3SBio Inc. Fundamentals Summary

How do 3SBio's earnings and revenue compare to its market cap?
1530 fundamental statistics
Market capHK$14.32b
Earnings (TTM)HK$2.09b
Revenue (TTM)HK$8.19b

6.8x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1530 income statement (TTM)
RevenueCN¥7.55b
Cost of RevenueCN¥1.24b
Gross ProfitCN¥6.31b
Other ExpensesCN¥4.38b
EarningsCN¥1.93b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.80
Gross Margin83.57%
Net Profit Margin25.55%
Debt/Equity Ratio30.9%

How did 1530 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

11%

Payout Ratio

Does 1530 pay a reliable dividends?

See 1530 dividend history and benchmarks
When do you need to buy 1530 by to receive an upcoming dividend?
3SBio dividend dates
Ex Dividend DateJul 22 2024
Dividend Pay DateAug 05 2024
Days until Ex dividend118 days
Days until Dividend pay date132 days

Does 1530 pay a reliable dividends?

See 1530 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.